Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054

Detalles Bibliográficos
Autores principales: Eggermont, Alexander, Kicinski, Michal, Suciu, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8768906/
https://www.ncbi.nlm.nih.gov/pubmed/35042824
http://dx.doi.org/10.1136/jitc-2021-004272
_version_ 1784635020320702464
author Eggermont, Alexander
Kicinski, Michal
Suciu, Stefan
author_facet Eggermont, Alexander
Kicinski, Michal
Suciu, Stefan
author_sort Eggermont, Alexander
collection PubMed
description
format Online
Article
Text
id pubmed-8768906
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-87689062022-02-04 Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 Eggermont, Alexander Kicinski, Michal Suciu, Stefan J Immunother Cancer Letter BMJ Publishing Group 2022-01-18 /pmc/articles/PMC8768906/ /pubmed/35042824 http://dx.doi.org/10.1136/jitc-2021-004272 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Letter
Eggermont, Alexander
Kicinski, Michal
Suciu, Stefan
Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054
title Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054
title_full Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054
title_fullStr Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054
title_full_unstemmed Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054
title_short Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054
title_sort association of selected (immune-related) adverse events and outcome in two adjuvant phase iii trials, checkmate-238 and eortc1325/keynote-054
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8768906/
https://www.ncbi.nlm.nih.gov/pubmed/35042824
http://dx.doi.org/10.1136/jitc-2021-004272
work_keys_str_mv AT eggermontalexander associationofselectedimmunerelatedadverseeventsandoutcomeintwoadjuvantphaseiiitrialscheckmate238andeortc1325keynote054
AT kicinskimichal associationofselectedimmunerelatedadverseeventsandoutcomeintwoadjuvantphaseiiitrialscheckmate238andeortc1325keynote054
AT suciustefan associationofselectedimmunerelatedadverseeventsandoutcomeintwoadjuvantphaseiiitrialscheckmate238andeortc1325keynote054

Ejemplares similares